BackFreeline Therapeutics Holdings plc Overview

Freeline Therapeutics Holdings plc Accounts Payable

Track Freeline Therapeutics Holdings plc's accounts payable ($7.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$7.78M
21.88% YoYΔ $-2.18M vs prior year quarter

Peer average

Loading

Freeline Therapeutics Holdings plc Accounts Payable History

Loading

Freeline Therapeutics Holdings plc vs. peers: Accounts Payable Comparison

Loading

Freeline Therapeutics Holdings plc Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Freeline Therapeutics Holdings plc (FRLN) FAQ

As of the most recent data (September 2023), FRLN shows a accounts payable of $7.8M. That compares with $10M in the prior-year period — down 21.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, FRLN's accounts payable is now $7.8M (was $10M) — a 21.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Freeline Therapeutics Holdings plc is outperforming or lagging.

Tracking FRLN's accounts payable over time shows whether Freeline Therapeutics Holdings plc is scaling, shrinking, or reshaping that part of the business. The current reading is $7.8M That compares with $10M in the prior-year period — down 21.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Freeline Therapeutics Holdings plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $7.8M) with ownership activity and broader fundamentals.

Freeline Therapeutics Holdings plc's accounts payable is $7.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.